The association of NSAID use with risk of atrial fibrillation
| Model 1* | Model 2† | ||||
|---|---|---|---|---|---|
| n | HR | 95% CI | HR | 95% CI | |
| Never use | 261 | 1 | (Ref.) | 1 | (Ref.) |
| Current use (days) | |||||
| ≤14 | 17 | 1.08 | (0.66 to 1.76) | 0.96 | (0.59 to 1.58) |
| 15–30 | 17 | 1.99 | (1.22 to 3.26) | 1.76 | (1.07 to 2.88) |
| >30 | 8 | 1.00 | (0.50 to 2.03) | 0.84 | (0.41 to 1.70) |
| Past use (days) | |||||
| ≤30 | 47 | 2.01 | (1.47 to 2.75) | 1.84 | (1.34 to 2.51) |
| 31–180 | 76 | 1.10 | (0.85 to 1.42) | 1.00 | (0.77 to 1.29) |
| >180 | 431 | 1.11 | (0.94 to 1.30) | 1.04 | (0.88 to 1.22) |
| No use | 815 | 1 | (Ref.) | 1 | (Ref.) |
| Dosage current use | |||||
| Low-medium dosage (PDD ≤1) | 24 | 1.09 | (0.73 to 1.64) | 0.97 | (0.65 to 1.46) |
| High dosage (PDD >1.0) | 18 | 1.33 | (0.83 to 2.11) | 1.27 | (0.80 to 2.03) |
*Adjusted for age at index date and sex.
†Additionally adjusted for baseline values of: systolic blood pressure, diastolic blood pressure, body mass index, total and HDL cholesterol, smoking status. Time dependent covariates include: blood pressure lowering drugs, history of myocardial infarction, presence of heart failure, prevalent diabetes.
HDL, high-density lipoprotein; n, number of atrial fibrillation cases; NSAID, non-steroidal anti-inflammatory drug; PDD, prescribed daily dosage.